These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14967398)

  • 1. Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy.
    Palomba S; Orio F; Russo T; Colao A; Lombardi G; Zullo F
    Fertil Steril; 2004 Feb; 81(2):476-8. PubMed ID: 14967398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis.
    Eviö S; Tarkkila L; Sorsa T; Furuholm J; Välimäki MJ; Ylikorkala O; Tiitinen A; Meurman JH
    Oral Dis; 2006 Mar; 12(2):187-93. PubMed ID: 16476042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis.
    Palomba S; Orio F; Colao A; di Carlo C; Sena T; Lombardi G; Zullo F; Mastrantonio P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1502-8. PubMed ID: 11932272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
    Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate in the treatment of postmenopausal osteoporosis.
    Hosking DJ; Favus M; Yates AJ
    Int J Clin Pract Suppl; 1999 Apr; 101():27-35. PubMed ID: 12669738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of special studies with alendronate.
    McClung M
    Int J Clin Pract Suppl; 1999 Apr; 101():67-72. PubMed ID: 12669743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spine studies to remain part of bone analysis.
    Diagn Imaging (San Franc); 1998 Nov; Suppl Bone Mass():6. PubMed ID: 10345144
    [No Abstract]   [Full Text] [Related]  

  • 15. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [FACT study: benefits of alendronate].
    MMW Fortschr Med; 2005 Jan; 147(1-2):52-3. PubMed ID: 15704574
    [No Abstract]   [Full Text] [Related]  

  • 17. [Modern osteoporosis therapy. Only once weekly against osteoporosis].
    MMW Fortschr Med; 2001 Jul; 143(28-29):52-3. PubMed ID: 11499150
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate in the treatment of osteoporosis.
    Adami S
    Aging (Milano); 1998 Apr; 10(2):159-60. PubMed ID: 9666215
    [No Abstract]   [Full Text] [Related]  

  • 20. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.